Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Research output: Contribution to journalJournal articleCommissionedpeer-review

Standard

Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. / EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA).

In: E F S A Journal, Vol. 12, No. 5, 3658, 2014.

Research output: Contribution to journalJournal articleCommissionedpeer-review

Harvard

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2014, 'Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006', E F S A Journal, vol. 12, no. 5, 3658. https://doi.org/10.2903/j.efsa.2013.3658

APA

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2014). Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. E F S A Journal, 12(5), [3658]. https://doi.org/10.2903/j.efsa.2013.3658

Vancouver

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. E F S A Journal. 2014;12(5). 3658. https://doi.org/10.2903/j.efsa.2013.3658

Author

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). / Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. In: E F S A Journal. 2014 ; Vol. 12, No. 5.

Bibtex

@article{294ac0e0456646f398226bf9f0d0817b,
title = "Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006",
abstract = "Following an application from PiLeJe, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort. The food that is the subject of the health claim is a combination of four bacterial strains—B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104. The Panel considers that the food, a combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104, which is the subject of the health claim is sufficiently characterised. The claimed effect proposed by the applicant is {"}improves intestinal comfort{"}. The Panel considers that reduction of gastro-intestinal discomfort is a beneficial physiological effect. The Panel considers that the only human study provided for the substantiation of the claim (with limitations) did not find an effect of a combination of the bacterial strains being the subject of the claim on gastrointestinal discomfort. The Panel concludes that a cause and effect relationship has not been established between the consumption of a combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104 and reducing gastro-intestinal discomfort.",
keywords = "Faculty of Science, Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103, Streptococcus thermophilus LA 104, Intestinal discomfort, Health claims",
author = "{EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)} and Inge Tetens and Sj{\"o}din, {Anders Mikael}",
year = "2014",
doi = "10.2903/j.efsa.2013.3658",
language = "English",
volume = "12",
journal = "E F S A Journal",
issn = "1831-4732",
publisher = "European Food Safety Authority (E F S A)",
number = "5",

}

RIS

TY - JOUR

T1 - Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006

AU - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

AU - Tetens, Inge

AU - Sjödin, Anders Mikael

PY - 2014

Y1 - 2014

N2 - Following an application from PiLeJe, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort. The food that is the subject of the health claim is a combination of four bacterial strains—B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104. The Panel considers that the food, a combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104, which is the subject of the health claim is sufficiently characterised. The claimed effect proposed by the applicant is "improves intestinal comfort". The Panel considers that reduction of gastro-intestinal discomfort is a beneficial physiological effect. The Panel considers that the only human study provided for the substantiation of the claim (with limitations) did not find an effect of a combination of the bacterial strains being the subject of the claim on gastrointestinal discomfort. The Panel concludes that a cause and effect relationship has not been established between the consumption of a combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104 and reducing gastro-intestinal discomfort.

AB - Following an application from PiLeJe, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort. The food that is the subject of the health claim is a combination of four bacterial strains—B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104. The Panel considers that the food, a combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104, which is the subject of the health claim is sufficiently characterised. The claimed effect proposed by the applicant is "improves intestinal comfort". The Panel considers that reduction of gastro-intestinal discomfort is a beneficial physiological effect. The Panel considers that the only human study provided for the substantiation of the claim (with limitations) did not find an effect of a combination of the bacterial strains being the subject of the claim on gastrointestinal discomfort. The Panel concludes that a cause and effect relationship has not been established between the consumption of a combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104 and reducing gastro-intestinal discomfort.

KW - Faculty of Science

KW - Bifidobacterium longum LA 101

KW - Lactobacillus helveticus LA 102

KW - Lactococcus lactis LA 103

KW - Streptococcus thermophilus LA 104

KW - Intestinal discomfort

KW - Health claims

U2 - 10.2903/j.efsa.2013.3658

DO - 10.2903/j.efsa.2013.3658

M3 - Journal article

VL - 12

JO - E F S A Journal

JF - E F S A Journal

SN - 1831-4732

IS - 5

M1 - 3658

ER -

ID: 186482083